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Objectives: We examined virological outcomes, patterns of acquired HIV drug resistance (ADR), correlates of
virological failure (VF) and acquired drug resistance among fisherfolk on first-line ART.
Methods: We enrolled 1169 adults on ART for a median duration of 6, 12, 24, 36 and 48 months and used a
pooled VL testing approach to identify VF (VL1000 copies/mL). We performed genotyping among VF cases and
determined correlates of VF and ADR by logistic regression.
Results: The overall virological suppression rate was 91.7% and ADR was detected in 71/97 (73.2%) VF cases.
The most prevalent mutations were M184V/I (53.6%) for NRTIs and K103N (39.2%) for NNRTIs. Thymidine ana-
logue mutations were detected in 21.6% of VF cases while PI mutations were absent. A zidovudine-based ART
regimen, duration on ART (24 months) and secondary/higher education level were significantly associated
with VF. A nevirapine-based regimen [adjusted OR (aOR): 1.87; 95% CI: 0.03–0.54)] and VL 10000 copies/mL
(aOR: 3.48; 95% CI: 1.37–8.85) were ADR correlates. The pooling strategies for VL testing with a negative predict-
ive value (NPV) of95.2% saved US $20320 (43.5%) in VL testing costs.
Conclusions: We observed high virological suppression rates among these highly mobile fisherfolk; however,
there was widespread ADR among those with VF at the first VL testing prior to intensive adherence counselling.
Timely treatment switching and adherence support is recommended for better treatment outcomes. Adoption
of pooled VL testing could be cost effective, particularly in resource-limited settings.
Introduction
ART is the cornerstone of HIV treatment and prevention.1 Provision
of ART is aimed at virological suppression in HIV-infected people,
reduction of HIV-associated morbidity and mortality and reduction
of HIV transmission.2 Maximizing virological suppression (the ‘third
90’) is cardinal in realizing the UNAIDS 90-90-90 target.3 Uganda
adopted the WHO approach of universal ‘test and treat’ and stand-
ardized regimens for first-line and second-line therapy.4 A more
potent first-line regimen comprising tenofovir disoproxil fumarate,
lamivudine and dolutegravir has recently been recommended for
adults.2
Increased HIV acquired drug resistance (ADR) and transmitted
drug resistance (TDR) following the scale-up of ART5,6 pose a threat
to the success of ART. ADR occurs when mutations emerge due to
viral replication in individuals on ART and this form of HIV drug re-
sistance (HIVDR) may occur due to suboptimal adherence to treat-
ment, treatment interruption, insufficient plasma drug
concentrations or the use of less efficacious drug regimens.7 A
high prevalence of ADR (71%) was reported among individuals fail-
ing the WHO-recommended NNRTI-based first-line regimen7,8
and, similarly, low virological suppression rates (50%–60%) were
observed among individuals on ART in Uganda.9 The WHO7
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reported a pooled prevalence of 68% ADR among individuals fail-
ing an NNRTI-based regimen with an overall virological suppres-
sion rate of 82% in low- and middle-income countries (LMICs). In
contrast, the emergence of ADR has almost ceased in some
resource-rich settings.10 To curb HIVDR and associated treatment
failure, routine viral load (VL) testing and resistance testing are rec-
ommended for monitoring ART2,7 but are inhibited by high costs.
Fisherfolk engage in high-risk sexual behaviour and are highly
mobile11 so fisherfolk in Uganda are disproportionately affected by
HIV.12,13 Whereas the national adult prevalence of HIV is 6.5%,9
HIV prevalence is over 25% among fisherfolk.12 This vulnerability is
also linked to the time spent away from home, accessibility to daily
cash, their demographic profile (most are sexually active youths),
readily available transactional sex11 and high alcohol consump-
tion.14 These factors limit fisherfolk’s access to HIV/AIDS preven-
tion, treatment and care services.15 We hypothesized that
fisherfolk on ART have suboptimal adherence to ART, low virologic-
al suppression rates and high prevalence of ADR. There is a paucity
of data on virological suppression rates and ADR among fisherfolk
in Uganda. We therefore determined virological suppression rates,
assessed ADR and determined the correlates of both virological
failure (VF) and ADR among fisherfolk on first-line ART. To save
costs involved in individual VL testing, we integrated pooled VL
testing16–18 in population surveillance of ADR.
Methods
Study design
In this cross-sectional study, we enrolled 1169 HIV-1-infected adults
(15 years old) who had been on ART for at least 6 months at the time of
enrolment. We randomly selected these participants from a multi-site co-
hort of 6000 participants of the HIV Molecular Epidemiology study that
aimed to determine HIV subtypes and transmission dynamics among both
high-risk and general populations in Uganda. Eligible participants attending
HIV care clinics in the fisherfolk communities were consecutively enrolled
for the study between August 2016 and March 2017. In this current study,
participants with a history of ART exposure for prevention of mother-to-
child transmission (PMTCT) or for post-exposure prophylaxis and those on a
second-line regimen were excluded as our objectives were focused on the
outcomes of the first-line regimen. Demographic and clinical data were
extracted from participants’ treatment records. We stratified participants
by median duration on ART of 6, 12, 24, 36 and48 months.
Pooled VL testing of plasma samples
We constituted pools of plasma from all participants and performed two
pooling strategies as previously described.16–18 First, we used mini-pools of
five samples each (generating 234 mini-pools) and then 10%10 matrix
pools of mini-pool samples above the threshold (VL .200 copies/mL) only.
VF for an individual sample was defined as VL 1000 copies/mL and this
translated to a VL of 200 copies/mL to define a positive mini-pool and
100 copies/mL for a positive matrix pool. From the 234 mini-pools, 120
pools (600 samples) had a VL of 200 copies/mL; these samples were
arranged in six 10%10 matrix pools, each with 100 samples. We resolved
the matrix pools as previously described.16–18 Briefly, we used results of col-
umn and row pools to guide on which individual sample to test first, thus
minimizing the number of individual tests and costs. We used the
CobasV
R
AmpliPrep/CobasV
R
TaqMan 48 system with a detection range of 20–
100000000 copies/mL to perform all VL tests. The mini-pool platform was
used for initial screening as we hypothesized that it had a higher sensitivity
and NPV than a 10%10 matrix pool. We addressed the issue of false
negatives by testing 21 randomly selected ‘negatives’ from each pooling
strategy, thus determining their NPV. Our negatives were samples with a VL
,1000 copies/mL and the positives were samples with a VL1000 copies/
mL.
HIV genotypic resistance testing
We performed genotypic resistance testing in the WHO-designated HIVDR
laboratory at the MRC/Uganda Virus Research Institute (UVRI) and London
School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit as
previously described.8 Briefly, RNA was extracted from 140lL of plasma
using a QIAGEN viral RNA extraction kit (QIAGEN, Hilden, Germany); reverse
transcription and complementary DNA synthesis were done with the super-
script III high-fidelity one step PCR Kit (Invitrogen) and, following nested
PCR, sequencing of the HIV-1 complete protease gene (1–99 amino acids)
and the reverse transcriptase gene (1–252 amino acids) was done. The
resulting chromatograms were base-called using a customized RECall soft-
ware program19 and drug resistance mutations (DRMs) were analysed
using the Stanford HIVdb Program using the 2009 WHO mutation list.20 For
quality control purposes, our laboratory is enrolled in the Virology Quality
Assurance Program and all sequences generated in the laboratory are
assessed for cross-contamination by phylogenetic analysis. Sequences
from this study were deposited in GenBank under accession numbers
MK371106–MK371202. HIVDR results were communicated to the facility
clinicians for participant management.
Statistical analysis
We performed statistical analyses using Stata v12 (StataCorp, TX, USA). To
assess the distributions of the independent variables, we used medians
(and IQRs) for the continuous variables and frequencies and proportions for
the categorical variables. We performed univariate logistic regression ana-
lysis to assess association of each of the independent potential correlates
with each outcome. Variables that had an OR with P0.15 were included
in multivariate logistic regression models together with age and sex as po-
tential confounders. The independent variables considered were: level of
education, marital status, ART regimen, duration on ART and VL. We pre-
sent the results of adjusted ORs (aORs) with 95% CI. Variables were consid-
ered significantly associated with the outcome if the P value for the aOR
was less than 0.05.
Ethical considerations
The HIV Molecular Epidemiology study was approved by the UVRI Research
and Ethics Committee [UVRI-REC Federalwide Assurance (FWA) No.
00001354] and the Uganda National Council for Science and Technology
(UNCST FWA No. 00001293). All participants were recruited voluntarily and
provided written informed consent.
Results
Study profile and participants
The study profile is presented in Figure 1. Among the 1169 partici-
pants, the median age was 36 years (IQR: 30–44), 648 (55.4%)
were women and the overall median time on ART was
24.0 months (IQR: 11.3–37.6). We enrolled 878 fisherfolk from
the island fishing sites and 291 from the mainland fish-landing
sites. Most (74.7%) of the participants were on tenofo-
vir! lamivudine! efavirenz/nevirapine (TDF!3TC! EFV/NVP),
24.1% on zidovudine! lamivudine! efavirenz/nevirapine
(ZDV!3TC! EFV/NVP) and 1.2% were on other first-line ART com-
binations. Details of the participants’ demographic and clinical
characteristics are summarized in Table 1.
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Prevalence of virological suppression and correlates
of VF
The overall virological suppression rate was 91.7% (1072/1169)
(Figure 1); virological suppression rates for specific durations on
ART were 88.7% (211/238), 91.6% (217/237), 93.3% (222/238),
93.0% (214/230) and 92.0% (208/226) for individuals on ART for
median durations of 6, 12, 24, 36 and 48 months respectively
(Figure 2).
We observed statistically significant associations between VF
and a number of factors (Table 2). Being 35 years or older (aOR:
0.65; 95% CI: 0.43–0.99; P"0.042), duration on ART of24 months
(aOR: 0.61; 95% CI: 0.39–0.97; P"0.035) and being on an
efavirenz-based regimen (aOR: 0.59; 95% CI: 0.34–0.91; P"0.02)
were protective against VF (Table 2). However, having attained
secondary/higher education (aOR: 2.42; 95% CI: 1.04–5.64;
P"0.041) and being on a zidovudine-based regimen (aOR: 2.10;
95% CI: 1.29–3.46; P"0.003) were risk factors for VF (Table 2).
Prevalence and patterns of acquired HIVDR
Of the 97 genotyped VF cases, we observed HIVDR in 71/97
(73.2%) individuals, yielding an overall ADR prevalence of 6.1%
(71/1169) in the sampled population. While all 71 (73.2%) partici-
pants had mutations conferring resistance to NNRTIs, 57 (58.8%)
had dual-class (both NRTI and NNRTI) mutations and 14 (14.4%)
had only NNRTI mutations. The most prevalent NRTI mutations
were M184V/I (53.6%), K65R (17.5%) and thymidine analogue
mutations (TAMs) were present in 21.6% of VF cases. The most
prevalent NNRTI mutations were K103N (39.2%), Y181C (19.6%)
and G190A (15.5%) (Figure 3).
Correlates of ADR
Among the VF cases, VL and drug regimen were independently
associated with ADR (Table 3). An efavirenz-based regimen, in
comparison with a nevirapine-based regimen, was protective
against ADR (aOR: 0.13; 95% CI: 0.03–0.54; P"0.005). Other char-
acteristics that were significantly associated with ADR were: current
VL 10000 copies/mL (aOR: 4.39; 95% CI: 1.53–12.56; P"0.032)
and a zidovudine-based regimen (aOR: 3.74; 95% CI: 1.12–12.50;
P"0.006) as shown in Table 3. We noted that all ADR was driven by
NNRTI (73.2%) and dual-class DRMs (58.8%) (Figure 3).
Stanford drug resistance scores at VF
Based on the Stanford drug resistance genotype scoring system
(GSS), zidovudine had the highest predicted susceptibility (82.5%),
followed by tenofovir (65%), among NRTIs. For NNRTIs, the pre-
dicted susceptibility to both nevirapine and efavirenz was 28.9%.
Cross-resistance to the second-generation NNRTIs etravirine and
rilpivirine occurred in 35% and 46.4% of the participants, respect-
ively (Figure 4).
NPV and cost-efficiency of pooled VL testing assay
For the mini-pool assay, all 21 suspected negatives had VL
,1000 copies/mL (true negatives), hence an NPV of 100%. Of the
21 suspected negatives from the 10%10 matrix pools, 20 were
true negatives, giving an NPV of 95.2%. Overall, we did 661 VL tests
of pooled and individual samples to resolve the 1169 participant
samples. We thus saved US $20320 of VL testing of 508 samples
(43.5%), given the current retail price of US $40 per VL test in
Uganda.
Discussion
Limited virological monitoring of ART programmes and the use of
low-genetic-barrier regimens enhance the emergence of ADR dur-
ing first-line ART and impede the realization of the UNAIDS 90-90-
90 targets. We report a higher overall virological suppression rate
(91.7%) than the UNAIDS 90% target3 among fisherfolk on first-
line ART in Uganda. Our results agree with those reported in na-
tional surveys conducted between 2014 and 2016 in Vietnam and
Zambia, where virological suppression rates of 90% were realized.7
However, our overall virological suppression rate was higher than
the pooled virological suppression rate (82.1%) reported by the
WHO from 2014 to 2017 in LMICs.7 We further noted improved
virological suppression with time on ART, which is in agreement
with the findings in resource-rich settings where virological sup-
pression rates increased up to 93% with increased duration on
ART.21 Our results also concur with the local findings in which high
prevalence of virological suppression (.80%) was achieved in
Ugandan individuals, closely monitored for adherence, based on
VL testing.22,23 The higher virological suppression rates in our study
could be due to improved access to HIV care services provided by
development partners to combat HIV in this high-risk population
of fisherfolk. In addition, the virological suppression rates were
high for all median durations on ART, which suggests that the
WHO first-line regimen is efficacious among individuals with opti-
mal adherence.
In this setting, independent correlates of VF, including age
35 years, an efavirenz-based regimen and being on ART for
24 months, were all protective, while a zidovudine-based regi-
men and, surprisingly, secondary/higher-level education were risk
factors for VF. We observed that most fisherfolk have low
1169 individuals on first-line ART, selected randomly from
five sites of fisherfolk cohort
1072 with VL<1000
copies/mL (suppressed)
97 successfully sequenced
97 with VL≥1000 copies/mL
(virological failure)
1169 individual plasma samples
retrieved from MRC/UVRI and
LSHTM-Entebbe and pooled for VL
testing
71 with HIV surveillance
DRMs (SDRMs) or ADR
Figure 1. Study profile. Of 1169 individuals analysed for virological sup-
pression, 1072 had virological suppression and 97 had virological failure,
of which 71 had ADR.
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education levels and those with secondary/higher-level education
with high prevalence of ADR are probably mobile groups such as
sex workers and other unemployed persons trying to make a living
in fishing communities. A recent study on the phylogeography of
HIV-1 suggests that Ugandan fishing communities are a sink for,
and not a source of, HIV virus from general populations,24 and this
could be the case with resistant variants as well. Young age has
been reported as a predictor of VF by other studies.23,25 Most
fisherfolk are young and sexually active, stay away from home for
long periods, engage in transactional sex11 and are involved in al-
coholism and drug abuse.14 These factors increase vulnerability to
HIV and limit access to HIV care services thus promoting subopti-
mal adherence and increasing the odds of VF.11,15 This calls for HIV
care services, like voluntary counselling and testing, and adher-
ence support that is tailored for the youth. In this study, the use of
a tenofovir regimen was protective against both VF and ADR,
Table 1. Demographic and clinical data of study participants
Characteristic
Median months on ART, n (%)
6 12 24 36 48 total
Overall 238 237 238 230 226 1169
Gender
male 116 (48.7) 109 (46.0) 101 (42.4) 92 (40.0) 103 (45.6) 521 (44.6)
female 122 (51.3) 128 (54.0) 137 (57.6) 138 (60.0) 123 (54.4) 648 (55.4)
Age group (years)
,35 126 (52.9) 112 (47.3) 106 (44.5) 83 (36.1) 86 (38.0) 513 (43.9)
35 112 (47.1) 125 (52.7) 132 (55.5) 147 (63.9) 140 (62.0) 656 (56.1)
Source
HIVCOMB 36 (15.1) 32 (13.5) 30 (12.6) 33 (14.4) 27 (12.0) 158 (13.5)
Kalangala-A 61 (25.6) 88 (37.1) 94 (39.5) 79 (34.3) 86 (38.1) 408 (34.9)
Kalangala-B 59 (24.8) 56 (23.6) 58 (24.4) 65 (28.3) 51 (22.6) 289 (24.7)
LaVIISWA 49 (20.6) 34 (14.4) 35 (14.7) 28 (12.2) 35 (15.5) 181 (15.5)
Masaka fisherfolk 33 (13.9) 27 (11.4) 21 (8.8) 25 (10.9) 27 (12.0) 133 (11.4)
Education level
none 44 (18.5) 25 (10.6) 34 (14.3) 46 (20.0) 40 (17.7) 189 (16.2)
primary 178 (74.8) 202 (85.2) 186 (78.2) 173 (75.2) 168 (74.3) 907 (77.6)
secondary/higher 16 (6.7) 10 (4.2) 18 (7.6) 11 (4.8) 18 (8.0) 73 (6.2)
Marital status
married 147 (61.8) 152 (64.1) 145 (60.9) 136 (59.1) 132 (58.4) 712 (60.9)
not married 91 (38.2) 85 (35.9) 93 (39.1) 94 (40.9) 94 (41.6) 457 (39.1)
On ART 238 237 238 230 226 1169
ART regimen (N"1155)
TDF!3TC! EFV/NVP 219/237 (92.4) 214/234 (91.5) 201 (84.5) 143/227 (63.0) 96/219 (43.8) 873/1155 (75.6)
ZDV!3TC! EFV/NVP 18/237 (7.6) 20/234 (8.5) 37 (15.5) 84/227 (37.0) 123/219 (56.2) 282/1155 (24.4)
3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine; LaVIISWA, The Lake Victoria Island Intervention Study on Worms
and Allergy-related diseases Project; HIVCOMB, HIV Combination Interventions Project.
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Figure 2. Prevalence of virological suppression was estimated for different median durations on ART. Virological suppression was defined as having
VL ,1000 copies/mL. The denominator was the number of individuals analysed at a given median duration on ART.
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Table 2. Correlates of VF among fisherfolk on first-line ART in Uganda
Characteristic VL1000 copies/mL, n/N (%) Unadjusted OR (95% CI) P value aOR P value
Gender
male 47/521 (9.0) 1
female 50/648 (7.7) 0.84 (0.56–1.29) 0.422 0.82 (0.53–1.25) 0.350
aAge group (years)
,35 52/513 (10.1) 1
35 45/656 (6.9) 0.65 (0.43–0.99) 0.045 0.64 (0.41–0.97) 0.042
Education level 0.056 0.043
never 13/189 (6.9) 1
primary 72/907 (7.9) 1.17 (0.63–2.15) 0.620 1.08 (0.58–2.00) 0.807
secondary/higher 12/73 (16.4) 2.66 (1.15–6.15) 0.022 2.42 (1.04–5.64) 0.041
bMarital status
married 57/712 (8.0) 1
not married 40/457 (8.7) 1.10 (0.72–1.68) 0.651
aART regimen
NVP versus EFV (NNRTIs)
NVP-based 31/295 (10.5) 1
EFV-based 66/880 (7.5) 0.70 (0.44–1.09) 0.048 0.59 (0.34–0.91) 0.020
TDF versus ZDV (NRTIs)
TDF!3TC!EFV/NVP 65/873 (7.4) 1
ZDV!3TC!EFV/NVP 32/282 (11.3) 1.59 (1.02–2.49) 0.041 2.10 (1.29–3.46) 0.003
Median months on ART
12 47/474 (9.9) 1
24 50/694 (7.2) 0.71 (0.47–1.07) 0.113 0.61 (0.39–0.97) 0.035
3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine. Statistically significant P values are shown in bold.
We classified the ART regimen into two categories, i.e. an NNRTI component (nevirapine-based versus efavirenz-based) and the second category
based on the NRTI component (tenofovir versus zidovudine). We report P values of other variables in the model where the NNRTI component was
included, although the statistical significance of the listed variables was maintained in the model in which we included the NRTI component (logistic
regression model results of other variables were excluded except for NRTI variables in this case).
aOnly variables with a P value of0.15 and a priori confounders (gender and age) were included in multivariate regression models.
bNot married means single, divorced or separated.
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probably because tenofovir-based regimens have been associated
with superior virological suppression and tolerability.26,27 Similarly,
better treatment outcomes have been associated with the use of
efavirenz rather than nevirapine as the NNRTI in first-line regi-
mens.28 Resistance to nevirapine is higher owing to its lower gen-
etic barrier compared with efavirenz.29 It is also possible that the
previous use of nevirapine for PMTCT could have been undisclosed
in females, increasing its resistance in this setting.
We report ADR prevalence of 73.2% among VF cases, mainly
attributed to NNRTI mutations known to drive HIVDR.8,30,31 This is
expected in settings where low-genetic-barrier NNRTIs are compo-
nents of first-line ART and these results are consistent with the
findings of Kaleebu et al.,8 who reported ADR prevalence of 71%
among VF cases on first-line ART in Uganda. Within East Africa, we
report a higher ADR prevalence than that previously reported in a
rural Kenyan cohort (52.7%) among VF cases,32 an observation
that was probably due to the longer median duration on ART of our
study participants compared with those in the Kenyan cohort
(24.0 versus 13.9 months). This supports the notion that prolonged
ART exposure increases the risk of emergence of ADR variants.33
Our results agree with the WHO pooled estimates of 68% ADR
among VF cases in LMICs7 and findings of other studies in
Africa6,34–36 and developed countries37 that have highlighted a sig-
nificant increase in drug resistance with time on ART. Increase in
HIVDR translates to failure of ART regimens/programmes,
increased morbidity and mortality, increased risk of transmission
of resistant virus strains and increased demand for ART regimen
switch to classes that are costly and inaccessible in resource-
limited settings like Uganda.
The DRM profiles reported here are similar to those docu-
mented earlier in this region where the first-line regimen combin-
ation includes two NRTIs and one NNRTI.7,8,30,34,37 The most
prevalent NRTI mutations, M184V/I, are selected by and cause
high-level resistance to cytosine analogue NRTIs, lamivudine and
emtricitabine.29,30 The K65R mutation, which is selected by lamiv-
udine and tenofovir,31 was highly prevalent among VF cases in our
study, which indicates the prolonged use of lamivudine and teno-
fovir in this setting. The rampant prevalence of the M184V/I and
K65R mutations may not warrant the discontinuation of NRTI
usage because these mutations confer increased susceptibility to
Table 3. Correlates of ADR in 97 fisherfolk failing on first-line ART in Uganda
Characteristic ADR, n/N (%) Unadjusted OR P value aOR P value
Gender
male 32/47 (68.1) 1
female 39/50 (78.0) 1.66 (0.67-4.12) 0.273 1.92 (0.66–5.55) 0.231
Age group (years)
,35 37/52 (71.2) 1
35 34/45 (75.6) 1.25 (0.51–3.10) 0.626 1.64 (0.55–4.92) 0.373
Education level 0.535
never 11/13 (84.6) 1
primary 52/72 (72.2) 0.47 (0.10–2.32) 0.356
secondary/higher 8/12 (66.7) 0.36 (0.53–2.50) 0.303
aMarital status
married 38/57 (66.7) 1
not married 33/40 (82.5) 2.36 (0.88–6.31) 0.088 2.10 (0.69–6.37) 0.192
bART regimen
NVP versus EFV (NNRTI backbone)
NVP-based 28/31 (90.3) 1
EFV-based 43/66 (65.1) 0.20 (0.05–0.73) 0.015 0.13 (0.03–0.54) 0.005
TDF versus ZDV (NRTI main component)
TDF!3TC! EFV/NVP 44/65 (67.7) 1
ZDV!3TC! EFV/NVP 27/32 (84.4) 2.58 (0.87–7.64) 0.088 3.74 (1.12–12.50) 0.032
Median months on ART
12 35/47 (74.5) 1
24 36/50 (72.0) 0.88 (0.36–2.17) 0.784
bVL (copies/mL)
,10000 20/35 (57.1) 1
10000 51/62 (82.3) 3.48 (1.37–8.85) 0.009 4.39 (1.53–12.56) 0.006
3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine. Statistically significant P values are shown in bold.
aNot married means single, divorced or separated.
bFor ART regimen, subvariables (a) and (b) were entered in different multivariate logistic models since they are interacting variables. In both models,
the bold P values remained statistically significant for other correlates. The reported P values are those in the model where nevirapine versus efavir-
enz was included. Only variables with a P value 0.15 and a priori confounders in univariate analysis (gender and age) were included in multivariable
regression models.
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zidovudine (a second-line regimen component in Uganda2) and
reduced virological fitness to HIV.31 On the other hand, emtricita-
bine and lamivudine remain preferable because of their tolerabil-
ity1,29 and as such they may still be useful components of the
second-line regimen in Uganda.2 The high prevalence of TAMs
(21.6%) is of concern because they confer cross-resistance to other
NRTIs. However, the second-line regimen would be efficacious in
such individuals, especially when combined with PIs38 or with
dolutegravir.2,4 The use of dolutegravir has recently been recom-
mended in first-line ART regimens in Uganda2 to address the low
treatment efficacy and escalating drug resistance to NNRTIs.39
Timely switching of individuals failing NNRTI-based first-line ART
has the benefit of preserving NRTI components for use in a se-
cond-line regimen.7
All individuals with ADR had NNRTI mutations with K103N/S,
Y181C, K101E/Q and G190S/A being more prevalent, depicting ex-
tensive use of the NNRTIs nevirapine and efavirenz in first-line regi-
mens in this setting.8 Nevirapine and efavirenz have a low genetic
barrier to resistance in that one mutation generates resistance
to nevirapine and two mutations generate resistance to efavir-
enz.29,30 This probably explains why an efavirenz-based regimen
was protective against ADR compared with a nevirapine-based
regimen. The GSS showed cross-resistance of 46.4% and 35% to
the second-generation NNRTIs rilpivirine and etravirine, respective-
ly, which were not used in this cohort. These findings support the
replacement of NNRTIs with dolutegravir in the first-line regimen
as outlined in Uganda’s new HIV treatment guidelines.2 The
increasing HIVDR associated with NNRTIs, the superior efficacy of
dolutegravir due to a higher genetic barrier and its better tolerabil-
ity support the introduction of dolutegravir in the first-line
therapy.2
Individuals with a VL10000 copies/mL were at higher odds of
developing ADR compared with those with a VL ,10000 copies/
mL. We set this threshold based on findings that the risk of resist-
ance selection peaks at a VL of 10000 copies/mL.40 Our findings
therefore reiterate the need for maximum virological suppression
if ADR is to be controlled.3
Among VF cases, we report the absence of DRMs in 26.8% of
our participants, which is similar to findings of other studies in
which some VF cases lacked DRMs.8,41 This suggests interrupted
treatment and/or non-adherence and underscores the need for
routine VL monitoring and genotypic resistance testing, otherwise
these individuals could have been unnecessarily switched to a
costly second-line regimen.
In Uganda, VL tests are recommended 6 months after ART initi-
ation and then annually for suppressed adults. Individuals with VF
are given three intensive adherence counselling (IAC) sessions,
1 month apart, and a repeat VL test 1 month after the third ses-
sion. If VF persists, individuals are offered a regimen switch where-
as those with virological suppression are maintained on their
regimen with adherence support.2 In this first VL testing that
detected 97 VF cases in our cohorts, IAC was unnecessary in 73.2%
of VF cases with ADR. Worse still, the current ART guidelines2 do
not recommend genotypic resistance testing for individuals failing
on a first-line regimen, yet IAC alone cannot detect ADR and could
delay regimen switch. Early detection of HIVDR and timely switch-
ing to a second-line regimen prevents accumulation of DRMs in
patients failing on a first-line regimen.42 The omission (in Uganda’s
current ART policy) of genotypic resistance testing at the time of
first-line failure to guide regimen switch is due to high costs.43
However, genotypic resistance testing helps clinicians select the
most efficacious regimen thus preventing VF and accumulation of
HIVDR.29,44 In this study, both VL testing and genotypic resistance
testing were vital in monitoring first-line ART.
These findings should be interpreted in the light of several cav-
eats. First, being a cross-sectional survey, we diagnosed VF using
one plasma VL estimation yet at least two are preferable.2
Consequently, blips in VL that occur even during effective treat-
ment35 may have been mistaken for VF. Additionally, our cross-
sectional analysis does not include participants lost to follow-up or
participants who died during the course of treatment and as such
our virological suppression rates may be overestimated. We
excluded individuals with virological suppression from genotypic
resistance testing yet a recent study in Kenya showed virological
suppressors had accumulated DRMs.45 The effect of pre-
treatment drug resistance known to contribute to VF in clients on
ART41,46 was not analysed. A recent WHO survey indicated that
the prevalence of pre-treatment HIVDR in Uganda was 15.4%;7
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Figure 4. Predicted efficacy of NRTIs and NNRTIs after VF among 97 individuals on NNRTI-based first-line ART. The predicted susceptibility and resist-
ance is based on Stanford genotype susceptibility scores.
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the results from this survey and other countries led to changes in
treatment guidelines.2 Another previous study estimated the
prevalence of pre-treatment HIVDR among fisherfolk to be be-
tween 5% and 15% (moderate) for NNRTIs and ,5% (low) for
NRTI- and PI-based regimens.47 Lastly, Sanger sequencing may
have missed minority variants that have been associated with VF
and HIVDR.48 Despite those shortcomings, the general concepts
and observations highlighted in this study may still be applicable in
other settings including those whose HIV ART regimens and poli-
cies differ from ours.
The strength of this study was the use of a large multi-site sam-
ple size involving fisherfolk from both onshore and island fishing
sites. To our knowledge, this is the first study in Uganda to inte-
grate cost-saving pooled VL testing in population surveillance of
ADR and document virological suppression and ADR among fisher-
folk. Pooled VL testing has demonstrated efficiency with both
plasma and dried-blood spot (DBS) samples in settings where VF is
less than 25%,16,17 and thus is feasible in our setting with similar
conditions. In other African settings similar to ours, Newman
et al.49 used a qualitative mini-pool for detection of VF and HIVDR
in South African patients on first-line ART, while Pannus et al.50
combined pooled testing with DBS samples in a Malawian hospital;
both studies reported appreciable feasibility and cost efficiency.
However, there is a need to address barriers such as inadequate
resources, lack of validated pooling protocols usable by all labora-
tories and limited experienced manpower in VL pooling.
Consequently, the designs and application prospects of pooling
strategies are dependent on resource availability, local laboratory
needs and assurance of reliable turnaround time of results.
Conclusions
In this study, based on the first VL testing done before IAC, we re-
port high virological suppression rates among highly vulnerable
and mobile fisherfolk; but with widespread ADR among VF cases.
The three sessions of IAC and repeat VL testing without genotypic
resistance testing, as currently recommended in Uganda for po-
tential first-line VF cases, need to be revisited. We therefore recom-
mend timely treatment switching and adherence support guided
by routine VL testing and genotypic resistance testing for better
treatment outcomes. The adoption of pooled VL testing could be
cost-effective for monitoring of ART programmes, especially in
resource-limited settings.
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